Immunic (IMUX) to Release Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Immunic to post earnings of ($0.22) per share for the quarter.

Immunic Price Performance

NASDAQ:IMUX opened at $1.05 on Thursday. The firm has a market capitalization of $94.58 million, a PE ratio of -0.85 and a beta of 1.87. The business’s fifty day moving average price is $1.02 and its 200 day moving average price is $1.26. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11.

Analyst Ratings Changes

Several brokerages have commented on IMUX. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday, February 10th. HC Wainwright assumed coverage on shares of Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Immunic currently has a consensus rating of “Buy” and an average target price of $12.67.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.